525 Executive Boulevard
Elmsford, NY 10523
United States
914 233 3004
https://www.nanovibronix.com
Secteur(s): Healthcare
Secteur d’activité: Medical Devices
Employés à temps plein: 10
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Brian M. Murphy | CEO & Director | 342,5k | S.O. | 1957 |
Mr. Stephen R. Brown CPA | Chief Financial Officer | 276,5k | S.O. | 1956 |
Dr. Harold Jacob M.D. | Chief Medical Officer & Director | S.O. | S.O. | 1954 |
Mr. Amir Rippel | Vice President of Marketing | S.O. | S.O. | S.O. |
Ms. Lindsey Harrison | Vice President of Sales | S.O. | S.O. | S.O. |
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.
L’ISS Governance QualityScore de NanoVibronix, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..